原标题：人车流量持续攀升 综合效益加快显现港珠澳大桥日益成为大湾区发展"纽带"（奋进强国路 阔 步新征程·重大工程巡礼）一桥连三地，天堑变通途。 港珠澳大桥车来车往、节奏繁忙——客流总量再创新高。 截至10月4日0时45分，今年经港珠澳大桥珠海公路口岸出入境的客流总量首次突破2000万人次，同比增 长达86%，超过去年全年总量。 车流量刷新单日纪录。 10月5日，港珠澳大桥通行车辆超2.12万辆次，其中港澳单牌车超过1.45万辆次。 习近平总书记强调："对港珠澳大桥这样的重大工程，既要高质量建设好，全力打造精品工程、样板工 程、平安工程、廉洁工程，又要用好管好大桥，为粤港澳大湾区建设发挥重要作用。 "2018年10月23日，港珠澳大桥正式开通。 近6年来，这一创下多项世界之最的"国之重器"，日益成为粤港澳大湾区发展的"纽带"。 人员往来更便捷，城市联系更紧密"早上，经港珠澳大桥，到珠海喝早茶；中午，到中山参观游览；晚 上，走深中通道到深圳吃晚饭，再返回香港。 "今年暑假，香港市民黎先生带着孩子体验粤港澳大湾区"一日游"，"一天转了三座城市、打卡两座超级 工程，感觉很棒！ ""港澳车辆'北上'政策落地1年多来， ...

Clinical Study Results - The primary endpoint of the 12-week induction period was met in a Phase 2 clinical study of picankibart (IBI112) for treating moderately to severely active ulcerative colitis (UC) in Chinese subjects [1] - The study enrolled 150 subjects randomized to receive placebo, picankibart 200 mg, or picankibart 600 mg during the induction period [2] - Clinical remission rates at week 12 were 20.0% for the 200 mg group and 14.0% for the 600 mg group, significantly higher than the 2.0% in the placebo group (p < 0.05) [3] - Clinical response rates were 54.0% for the 200 mg group and 68.0% for the 600 mg group, significantly higher than the 22.0% in the placebo group (p < 0.001) [3] - The maintenance period is ongoing, with continued increases in clinical remission, response, and other efficacy measures compared to the induction period [4] Picankibart (IBI112) Development - Picankibart is a recombinant anti-IL-23p19 antibody injection developed by Innovent [1] - It has shown potential for treating psoriasis, ulcerative colitis, and other autoimmune diseases [7] - Multiple clinical studies are underway, including Phase 3 studies for plaque psoriasis and Phase 2 studies for UC [7] - The NMPA accepted the first NDA for picankibart for treating moderate to severe plaque psoriasis in September 2024 [8] Ulcerative Colitis Market - UC is a chronic inflammatory disease with increasing prevalence in China, currently at 11.6/100,000 [6] - Current treatments include traditional immunosuppressants and biologics, but there are unmet needs due to adverse reactions and loss of response [6] - No IL-23p19 targeted drugs are approved for UC treatment in China, representing a significant market opportunity [6] Innovent Biologics Overview - Innovent is a leading biopharmaceutical company founded in 2011, focusing on oncology, autoimmune, cardiovascular, metabolic, and ophthalmology diseases [9] - The company has launched 11 products, with 5 NDAs under regulatory review and 3 assets in Phase III or pivotal trials [9] - Innovent has partnerships with over 30 global healthcare companies, including Eli Lilly, Sanofi, and Incyte [9]

SAN FRANCISCO and SUZHOU, China, Oct. 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, and Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm, 002755.SZ), announced that the two parties have entered into a strategic collaboration regarding limertinib, a thi ...

SAN FRANCISCO and SUZHOU, China, Sept. 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for picankibart injection, a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody, has been accepted by the Center f ...

SAN FRANCISCO and SUZHOU, China, Sept. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that clinical data of IBI363 (first-in-class PD1/IL-2α-bias bispecific antibody fusion protein) combined with bevacizumab in advanced colorectal cancer is present ...

SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the Phase 3 clinical trial results for mazdutide, a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with ...

SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announced the presentation of Phase 1 clinical data (ClinicalTrials.gov, NCT04085185) for IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) in adva ...

SAN FRANCISCO and SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces an oral presentation of updated results from a pivotal Phase 2 clinical trial of Dupert®（fulzerasib）for the treatment of adult patients with advanced non-small cel ...

SAN FRANCISCO and SUZHOU, China, Sept. 1, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that multiple clinical study results of mazdutide (GLP1R/GCGR dual agonist) will be presented at the European Association for the Study of Diabetes® (EASD) 60th An ...

SAN FRANCISCO and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that nearly 20 accepted clinical data of its novel oncology molecules, including six oral presentations, will be released at World Conference on Lung Cancer (WCLC) ...